Thomas Kim - 15 Jun 2022 Form 4 Insider Report for Enfusion, Inc.

Role: Chief Executive Officer, Director
Signature: /s/ Blake Nielsen, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 15 Jun 2022
Net transactions value: $0
Form type: 4
Filing time: 17 Jun 2022, 21:46:38 UTC
Previous filing: 21 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENFN	Class A Common Stock	Award	$0	+20,284	+2.4%	$0.000000	865,872	15 Jun 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENFN	Stock Option (Right to Buy)	Award	$0	+32,000		$0.000000	32,000	15 Jun 2022	Class A Common Stock	32,000	$9.86	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consist of restricted stock units ("RSUs") awarded pursuant to the Enfusion, Inc. 2021 Stock Option and Incentive Plan (the "Plan"). The restricted stock units will vest in full as follows: 6,762, 6,761 and 6,761 restricted stock units will vest on June 15, 2023, June 15, 2024 and June 15, 2025, respectively.
F2	These options were granted under the Plan and shall become exercisable as follows: 10,667, 10,667 and 10,666 on June 15, 2023, June 15, 2024 and June 15, 2025, respectively.